美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Inspire Corporate Bond ETF

23.79

+0.02000.08%

盤後：23.790.00000.00%18:34 EDT

成交量：5.48萬

成交額：130.46萬

市值：3.83億

市盈率：- -

高：23.89

開：23.81

低：23.75

收：23.77

資料載入中...

總覽公司新聞公告

Organovo Holdings, Inc.盤中異動下午盤快速下跌6.37%報0.422美元

Organovo Holdings, Inc.盤中異動快速下挫6.10%

艾伯維殺入減重賽道尋找下一個“藥王”？

Organovo Holdings, Inc.股價重挫10.77% 市值跌109.04萬美元

Organovo Holdings, Inc.盤中異動早盤大幅跳水5.55%

Organovo Holdings, Inc.盤中異動早盤股價大跌8.09%

Organovo Holdings, Inc.股價拉昇11.82% 市值漲292.98萬美元

Organovo Holdings, Inc.股價上漲238.75% 市值漲5209.05萬美元

Organovo Holdings, Inc.盤中異動股價大跌5.15%報0.350美元

Organovo Holdings, Inc.盤中異動股價大跌5.51%

Organovo Holdings, Inc.盤中異動股價大跌5.96%報0.363美元

Organovo Holdings, Inc.盤中異動股價大漲5.82%報0.400美元

Organovo Holdings, Inc.盤中異動早盤快速拉昇5.02%

MNC年報掃描｜巨頭“廝殺” 國產“逐鹿”：自免領域5大單品狂攬近530億美元

21世纪经济报道

【禮來(LLY.US)IL-23p19單抗mirikizumab獲批克羅恩病新適應症】1月15日，禮來(LLY.US)宣佈，其IL-23p19單抗mirikizumab(Omvoh)已獲FDA批准第2項適應症，用於治療成人中度至重度活動性克羅恩病。Mirikizumab繼2023年10月被批准為治療中度至重度活動性成人潰瘍性結腸炎(UC)的同類首創療法之後，現在又被批准用於治療兩種類型的炎症性腸病(IBD)。

MNC年度漲幅榜，意外的榜一

醫藥行業週報：艾伯維將以2億美元收購NIMBLE 佈局自免領域

太平洋证券股份...

分析師：若CPI報告糟糕，美聯儲和市場也不會過於看重

武田掀起新一輪裁員潮！專利懸崖、管線調整之後，整合能否找到出路？

医药经济报

信達生物宣佈匹康奇拜單抗（IL-23p19抗體）治療潰瘍性結腸炎的II期臨牀研究達成主要終點

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/IBD/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IBD","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBD\",,,,,undefined,":{"symbol":"IBD","market":"US","secType":"STK","nameCN":"Inspire Corporate Bond ETF","latestPrice":23.79,"timestamp":1743624000000,"preClose":23.77,"halted":0,"volume":54848,"hourTrading":{"tag":"盘后","latestPrice":23.79,"preClose":23.79,"latestTime":"18:34 EDT","volume":4,"amount":95.16,"timestamp":1743633291706},"delay":0,"floatShares":16100000,"shares":16100000,"eps":0,"marketStatus":"已收盤","change":0.02,"latestTime":"04-02 16:00:00 EDT","open":23.81,"high":23.89,"low":23.75,"amount":1304614.5280000002,"amplitude":0.00589,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1743667200000},"marketStatusCode":5,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":23.77,"sharesOutstanding":16100000,"nav":23.77,"aum":382639341.88,"bidAskSpread":0.002765,"preHourTrading":{"tag":"盘前","latestPrice":23.77,"preClose":23.77,"latestTime":"08:47 EDT","volume":7,"amount":166.39,"timestamp":1743598023825},"postHourTrading":{"tag":"盘后","latestPrice":23.79,"preClose":23.79,"latestTime":"18:34 EDT","volume":4,"amount":95.16,"timestamp":1743633291706},"volumeRatio":0.655587},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IBD\",,,,,undefined,":{"symbol":"IBD","floatShares":16100000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.655587,"shares":16100000,"dividePrice":0.9757,"high":23.89,"amplitude":0.00589,"preClose":23.77,"low":23.75,"week52Low":22.84,"pbRate":"--","week52High":25.49,"institutionHeld":0,"latestPrice":23.79,"eps":0,"divideRate":0.041013,"volume":54848,"delay":0,"ttmEps":0,"open":23.81,"prevYearClose":23.44,"prevWeekClose":23.7,"prevMonthClose":23.75,"prevQuarterClose":23.75,"fiveDayClose":23.745,"twentyDayClose":23.71,"sixtyDayClose":23.5},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IBD\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2518420501","title":"Organovo Holdings, Inc.盤中異動 下午盤快速下跌6.37%報0.422美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518420501","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518420501?lang=zh_tw&edition=fundamental","pubTime":"2025-03-11 01:05","pubTimestamp":1741626341,"startTime":"0","endTime":"0","summary":"北京时间2025年03月11日01时05分，Organovo Holdings, Inc.股票出现异动，股价大幅下挫6.37%。截至发稿，该股报0.422美元/股，成交量27.3231万股，换手率1.57%，振幅8.70%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.64%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311010542abf34a26&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311010542abf34a26&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBD","BK4139","ONVO"],"gpt_icon":0},{"id":"2517908945","title":"Organovo Holdings, Inc.盤中異動 快速下挫6.10%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517908945","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517908945?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 22:43","pubTimestamp":1741185821,"startTime":"0","endTime":"0","summary":"北京时间2025年03月05日22时43分，Organovo Holdings, Inc.股票出现波动，股价急速下挫6.10%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.75%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305224341963adf65&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305224341963adf65&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBD","BK4139","ONVO"],"gpt_icon":0},{"id":"2516260096","title":"艾伯維殺入減重賽道 尋找下一個“藥王”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2516260096","media":"新京报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516260096?lang=zh_tw&edition=fundamental","pubTime":"2025-03-04 18:00","pubTimestamp":1741082458,"startTime":"0","endTime":"0","summary":"艾伯维还是杀入了减重赛道。美国时间3月3日，艾伯维宣布与Gubra公司达成许可协议，共同开发用于治疗肥胖症的潜在同类最佳长效胰淀素类似物，交易总额最高可达22亿美元。当前减重赛道火热，2024年两款全球畅销减重药物更是合计卖出了457.42亿美元。自旗下修美乐因专利到期等因素销售开始下滑后，艾伯维业绩受到影响，近年来也在频频对外合作，提振业绩。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202503043336126264.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503043336126264.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBD"],"gpt_icon":0},{"id":"2516634704","title":"Organovo Holdings, Inc.股價重挫10.77% 市值跌109.04萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2516634704","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516634704?lang=zh_tw&edition=fundamental","pubTime":"2025-03-03 22:30","pubTimestamp":1741012250,"startTime":"0","endTime":"0","summary":"北京时间2025年03月03日22时30分，Organovo Holdings, Inc.股票出现异动，股价大幅下跌10.77%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032230509637ab9c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202503032230509637ab9c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBD","ONVO","BK4139"],"gpt_icon":1},{"id":"2514583373","title":"Organovo Holdings, Inc.盤中異動 早盤大幅跳水5.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514583373","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514583373?lang=zh_tw&edition=fundamental","pubTime":"2025-02-28 22:51","pubTimestamp":1740754266,"startTime":"0","endTime":"0","summary":"北京时间2025年02月28日22时51分，Organovo Holdings, Inc.股票出现异动，股价急速下挫5.55%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.22%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022822510696341eaf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025022822510696341eaf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBD","ONVO","BK4139"],"gpt_icon":1},{"id":"2514385603","title":"Organovo Holdings, Inc.盤中異動 早盤股價大跌8.09%","url":"https://stock-news.laohu8.com/highlight/detail?id=2514385603","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514385603?lang=zh_tw&edition=fundamental","pubTime":"2025-02-27 22:37","pubTimestamp":1740667027,"startTime":"0","endTime":"0","summary":"北京时间2025年02月27日22时37分，Organovo Holdings, Inc.股票出现波动，股价急速下挫8.09%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.85%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272237079632b21c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502272237079632b21c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","ONVO","IBD"],"gpt_icon":1},{"id":"2514518578","title":"Organovo Holdings, Inc.股價拉昇11.82% 市值漲292.98萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514518578","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514518578?lang=zh_tw&edition=fundamental","pubTime":"2025-02-26 22:32","pubTimestamp":1740580349,"startTime":"0","endTime":"0","summary":"北京时间2025年02月26日22时32分，Organovo Holdings, Inc.股票出现异动，股价快速拉升11.82%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.20%。其相关个股中，Enveric Biosciences, Inc.、Nutriband Inc C/Wts 、Channel Therapeutics Corporation涨幅较大，Enveric Biosciences, Inc.、Organovo Holdings, Inc.、Cns Pharmaceuticals, Inc.较为活跃，换手率分别为2837.58%、119.45%、90.45%，振幅较大的相关个股有Enveric Biosciences, Inc.、Channel Therapeutics Corporation、Cns Pharmaceuticals, Inc.，振幅分别为35.59%、16.86%、14.35%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223230a254f6af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250226223230a254f6af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBD","BK4139","ONVO"],"gpt_icon":0},{"id":"2514090481","title":"Organovo Holdings, Inc.股價上漲238.75% 市值漲5209.05萬美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514090481","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514090481?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 22:31","pubTimestamp":1740493865,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日22时31分，Organovo Holdings, Inc.股票出现异动，股价急速上涨238.75%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.36%。其相关个股中，Organovo Holdings, Inc.、Moleculin Biotech, Inc.、Silexion Therapeutics Corp涨幅较大，Gt Biopharma, Inc.、Organovo Holdings, Inc.、Moleculin Biotech, Inc.较为活跃，换手率分别为746.23%、508.78%、459.72%，振幅较大的相关个股有Organovo Holdings, Inc.、Igm Biosciences, Inc.、Bicara Therapeutics Inc.，振幅分别为8.13%、7.46%、5.62%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223105abdc7da6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225223105abdc7da6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONVO","IBD","BK4139"],"gpt_icon":0},{"id":"2514670511","title":"Organovo Holdings, Inc.盤中異動 股價大跌5.15%報0.350美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2514670511","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514670511?lang=zh_tw&edition=fundamental","pubTime":"2025-02-25 04:35","pubTimestamp":1740429350,"startTime":"0","endTime":"0","summary":"北京时间2025年02月25日04时35分，Organovo Holdings, Inc.股票出现波动，股价快速跳水5.15%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体跌幅为0.14%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225043550962ee007&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250225043550962ee007&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBD","BK4139","ONVO"],"gpt_icon":0},{"id":"2512480684","title":"Organovo Holdings, Inc.盤中異動 股價大跌5.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2512480684","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512480684?lang=zh_tw&edition=fundamental","pubTime":"2025-02-20 01:31","pubTimestamp":1739986261,"startTime":"0","endTime":"0","summary":"北京时间2025年02月20日01时31分，Organovo Holdings, Inc.股票出现波动，股价快速下跌5.51%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.37%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220013101988b4e5d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250220013101988b4e5d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IBD","BK4139","ONVO"],"gpt_icon":0},{"id":"2512612521","title":"Organovo Holdings, Inc.盤中異動 股價大跌5.96%報0.363美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2512612521","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512612521?lang=zh_tw&edition=fundamental","pubTime":"2025-02-18 23:25","pubTimestamp":1739892328,"startTime":"0","endTime":"0","summary":"北京时间2025年02月18日23时25分，Organovo Holdings, Inc.股票出现波动，股价大幅下挫5.96%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.75%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218232528a24ab8fb&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250218232528a24ab8fb&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONVO","BK4139","IBD"],"gpt_icon":0},{"id":"2511137666","title":"Organovo Holdings, Inc.盤中異動 股價大漲5.82%報0.400美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2511137666","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511137666?lang=zh_tw&edition=fundamental","pubTime":"2025-02-15 02:04","pubTimestamp":1739556283,"startTime":"0","endTime":"0","summary":"北京时间2025年02月15日02时04分，Organovo Holdings, Inc.股票出现波动，股价大幅上涨5.82%。截至发稿，该股报0.400美元/股，成交量8.5386万股，换手率0.56%，振幅6.08%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体跌幅为0.50%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502150204439885bb0c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202502150204439885bb0c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONVO","IBD","BK4139"],"gpt_icon":0},{"id":"2511243345","title":"Organovo Holdings, Inc.盤中異動 早盤快速拉昇5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2511243345","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511243345?lang=zh_tw&edition=fundamental","pubTime":"2025-02-13 23:43","pubTimestamp":1739461383,"startTime":"0","endTime":"0","summary":"北京时间2025年02月13日23时43分，Organovo Holdings, Inc.股票出现波动，股价急速上涨5.02%。Organovo Holdings, Inc.股票所在的生物技术行业中，整体涨幅为0.50%。Organovo Holdings, Inc.公司简介：Organovo Holdings Inc是一家生物技术公司，专注于开发 FXR314 用于炎症性肠病，包括溃疡性结肠炎，其基础是在三维人体组织中展示了临床前景以及临床前数据。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213234303abcdc059&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250213234303abcdc059&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["ONVO","BK4139","IBD"],"gpt_icon":0},{"id":"2509791469","title":"MNC年報掃描｜巨頭“廝殺” 國產“逐鹿”：自免領域5大單品狂攬近530億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2509791469","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509791469?lang=zh_tw&edition=fundamental","pubTime":"2025-02-07 16:39","pubTimestamp":1738917574,"startTime":"0","endTime":"0","summary":"随着跨国药企（MNC）陆续披露2024年业绩，21世纪经济报道记者初步统计发现，自免领域的营收排名中，赛诺菲的度普利尤单抗、艾伯维的利生奇珠单抗和阿达木单抗、强生的乌司奴单抗、罗氏的奥瑞利珠单抗位居前5，年内销售额合计529.31亿美元。在这5款产品中，度普利尤单抗作为全球首个获批上市的IL-4Rα靶向单抗，凭借不断拓宽的适应症，成为全球“自免新王”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202502073313516026.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202502073313516026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["CD","BK4116","IBD"],"gpt_icon":0},{"id":"2503916699","title":"【禮來(LLY.US)IL-23p19單抗mirikizumab獲批克羅恩病新適應症】1月15日，禮來(LLY.US)宣佈，其IL-23p19單抗mirikizumab(Omvoh)已獲FDA批准第2項適應症，用於治療成人中度至重度活動性克羅恩病。Mirikizumab繼2023年10月被批准為治療中度至重度活動性成人潰瘍性結腸炎(UC)的同類首創療法之後，現在又被批准用於治療兩種類型的炎症性腸病(IBD)。","url":"https://stock-news.laohu8.com/highlight/detail?id=2503916699","media":"金融界","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2503916699?lang=zh_tw&edition=fundamental","pubTime":"2025-01-16 21:15","pubTimestamp":1737033339,"startTime":"0","endTime":"0","summary":"1月15日，礼来(LLY.US)宣布，其IL-23p19单抗mirikizumab(Omvoh)已获FDA批准第2项适应症，用于治疗成人中度至重度活动性克罗恩病。Mirikizumab继2023年10月被批准为治疗中度至重度活动性成人溃疡性结肠炎(UC)的同类首创疗法之后，现在又被批准用于治疗两种类型的炎症性肠病(IBD)。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/01/16211547534225.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK4585","LLY","LU0672654240.SGD","LU1868837300.USD","LU2264538146.SGD","LU1061106388.HKD","LU1057294990.SGD","LU0820561909.HKD","LU1712237335.SGD","SGXZ31699556.SGD","SG9999001176.SGD","LU0256863811.USD","IE00BK4W5L77.USD","LU2112291526.USD","SGXZ99366536.SGD","LU2461242641.AUD","LU2491049909.HKD","LU0203202063.USD","LU0122379950.USD","GB00BDT5M118.USD","LU1983299246.USD","LU2237443465.HKD","LU0820561818.USD","LU0109391861.USD","LU0823416689.USD","LU1974910355.USD","LU0079474960.USD","IE0002141913.USD","LU1069344957.HKD","LU0385154629.USD","LU1023059063.AUD","IE0004445239.USD","LU2237438978.USD","LU1988902786.USD","IE00BFTCPJ56.SGD","LU0006306889.USD","LU2491050071.SGD","LU2023250504.SGD","LU1035775433.USD","LU2237443978.SGD","IBD","BK4516","LU0320765059.SGD","LU0106261372.USD","LU2361045086.USD","SG9999001176.USD","LU0094547139.USD","LU0058720904.USD","LU2237443549.SGD","LU2063271972.USD"],"gpt_icon":0},{"id":"2502882548","title":"MNC年度漲幅榜，意外的榜一","url":"https://stock-news.laohu8.com/highlight/detail?id=2502882548","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502882548?lang=zh_tw&edition=fundamental","pubTime":"2025-01-10 14:58","pubTimestamp":1736492297,"startTime":"0","endTime":"0","summary":"都说铁打的大药企，流水的biotech。当超9成biotech跌跌不休之际，2022年全球领先的20家药企市值平均增长了5.4%。然而，到了2024年，大药企阵营也发生了分化。而股价涨幅最高的，则是仍处于转型爬坡阶段的梯瓦。整体来看，TOP20中，过去一年股价上涨与下跌企业各占一半。其中，梯瓦、礼来和吉利德是涨幅最高的三家大药企，拜耳、再生元和诺和诺德则是跌幅前三。真正的逆袭者，是以117%涨幅问鼎TOP20榜首的梯瓦。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/248993","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["IBD","BK4116","CD"],"gpt_icon":0},{"id":"2492588601","title":"醫藥行業週報：艾伯維將以2億美元收購NIMBLE 佈局自免領域","url":"https://stock-news.laohu8.com/highlight/detail?id=2492588601","media":"太平洋证券股份...","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492588601?lang=zh_tw&edition=fundamental","pubTime":"2024-12-17 00:00","pubTimestamp":1734364800,"startTime":"0","endTime":"0","summary":"行业要闻：近日，艾伯维宣布，将以2 亿美元现金收购Nimble，并提供一定的中期资金支持和里程碑付款，从而获得其核心资产口服肽类IL-23 受体IL-23R 抑制剂，以及覆盖多种自身免疫疾病的创新口服肽候选药物管线。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217120201ab7e131c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241217120201ab7e131c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE00BFTCPJ56.SGD","LU0985320562.USD","LU0211328371.USD","LU0965509010.AUD","LU1244550221.USD","LU1989772923.USD","BK4533","IE00BGHQF631.EUR","LU0310800379.SGD","LU1732799900.SGD","LU0310799852.SGD","LU0661504455.SGD","LU1057294990.SGD","SG9999003800.SGD","LU1267930490.SGD","LU0417517546.SGD","LU1003077747.HKD","SG9999011175.SGD","IBD","LU0128525929.USD","IE0002141913.USD","LU0689472784.USD","LU0553294199.USD","BK4585","LU1934455277.USD","LU2237443895.HKD","LU0965508806.USD","LU1496350171.SGD","LU0122379950.USD","IE0009355771.USD","LU2347655156.SGD","BK4139","BK4566","LU0795875169.SGD","LU0820561818.USD","LU0256863811.USD","IE00B42XCP33.USD","LU1732800096.USD","LU2237443622.USD","LU0965509283.SGD","LU0861579265.USD","LU1291159041.SGD","LU0949170772.SGD","ABBV","BK4550","LU2023251221.USD","LU0708994859.HKD","IE00BDGV0183.EUR","LU0256863902.USD","BK4559"],"gpt_icon":0},{"id":"2483754020","title":"分析師：若CPI報告糟糕，美聯儲和市場也不會過於看重","url":"https://stock-news.laohu8.com/highlight/detail?id=2483754020","media":"金十财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483754020?lang=zh_tw&edition=fundamental","pubTime":"2024-11-13 17:42","pubTimestamp":1731490979,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://flash-api.jin10.com/get_flash_list?channel=2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_jinshicaijing","symbols":["US5Y.BOND","SPXU","US30Y.BOND","US3Y.BOND","ESmain","US6M.BOND","HK0000934320.USD","SPY","BK4559","SSO","BK4585","UPRO","US12M.BOND","SH","IVV","US10Y.BOND","BK4504","OEX","US7Y.BOND","SDS","IBD","OEF","US2Y.BOND","BK4581","BK4534",".SPX","BK4588","BK4550"],"gpt_icon":0},{"id":"2478151690","title":"武田掀起新一輪裁員潮！專利懸崖、管線調整之後，整合能否找到出路？","url":"https://stock-news.laohu8.com/highlight/detail?id=2478151690","media":"医药经济报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2478151690?lang=zh_tw&edition=fundamental","pubTime":"2024-10-27 18:56","pubTimestamp":1730026591,"startTime":"0","endTime":"0","summary":"武田制药在经历今年多轮裁员后，正计划进一步缩减员工规模。业内人士分析，武田制药近期的裁员决策主要是受到专利到期所带来的市场冲击及其对财务状况的影响。对武田制药而言，当务之急是寻找并推出下一代的主力产品。尽管武田制药通过专利诉讼试图延缓Vyvanse的专利到期，但这一努力并未能有效缓解利润下降的压力。自公布重组计划以来，武田制药已经启动了一连串的裁员措施。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241027190022a1eef4bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241027190022a1eef4bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["TAK","ADHD","IG","BK4007","CD","BK4116","IBD"],"gpt_icon":0},{"id":"2476251188","title":"信達生物宣佈匹康奇拜單抗（IL-23p19抗體）治療潰瘍性結腸炎的II期臨牀研究達成主要終點","url":"https://stock-news.laohu8.com/highlight/detail?id=2476251188","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2476251188?lang=zh_tw&edition=fundamental","pubTime":"2024-10-17 08:00","pubTimestamp":1729123200,"startTime":"0","endTime":"0","summary":"我很高兴看到匹康奇拜单抗治疗中重度活动性溃疡性结肠II期临床研究中达成主要终点，受试者获得显著的诱导期临床获益，同时安全性良好。近年来，以IL-23为靶点的新一代药物因其在溃疡性结肠炎患者治疗中卓越的疗效和良好的安全性引发关注；目前，国内市场上尚无IL-23p19靶点药物获批治疗溃疡性结肠炎，本研究是第一个由国内企业自主研发的IL-23p19单抗治疗溃疡性结肠炎的临床研究。溃疡性结肠炎严重威胁身体健康并对日常生活和心理带来影响。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4532408_ZH32408_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["01801","LU2328871848.SGD","IVBIY","BK1161","LU1969619763.USD","BK1589","BK4139","IBD","BK1583","LU2488822045.USD"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":20}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IBD\",params:#limit:5,,,undefined,":[{"date":"2025-03-27","symbol":"IBD","amount":0.092,"announcedDate":"2025-03-26","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-27","defaultRemindTime":1743082200000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-27","currency":"USD","dateTimestamp":1743048000000,"payDate":"2025-04-01"},{"date":"2025-02-24","symbol":"IBD","amount":0.0728,"announcedDate":"2025-02-21","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-02-24","defaultRemindTime":1740407400000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-03-03","payableDate":"2025-02-24","currency":"USD","dateTimestamp":1740373200000,"payDate":"2025-03-03"},{"date":"2025-01-27","symbol":"IBD","amount":0.0599,"announcedDate":"2025-01-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-01-27","defaultRemindTime":1737988200000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-02-03","payableDate":"2025-01-27","currency":"USD","dateTimestamp":1737954000000,"payDate":"2025-02-03"},{"date":"2024-12-16","symbol":"IBD","amount":0.1181,"announcedDate":"2024-12-13","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-12-16","defaultRemindTime":1734359400000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-12-23","payableDate":"2024-12-16","currency":"USD","dateTimestamp":1734325200000,"payDate":"2024-12-23"},{"date":"2024-11-22","symbol":"IBD","amount":0.0748,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-11-22","defaultRemindTime":1732285800000,"name":"Inspire Corporate Bond ETF","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-11-29","payableDate":"2024-11-22","currency":"USD","dateTimestamp":1732251600000,"payDate":"2024-11-29"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IBD\",market:\"US\",,,undefined,":[{"executeDate":"2017-08-16","recordDate":"2017-08-18","paymentDate":"2017-08-23","value":0.0405,"currency":"USD"},{"executeDate":"2017-09-18","recordDate":"2017-09-19","paymentDate":"2017-09-25","value":0.0292,"currency":"USD"},{"executeDate":"2017-10-16","recordDate":"2017-10-17","paymentDate":"2017-10-23","value":0.0347,"currency":"USD"},{"executeDate":"2017-11-16","recordDate":"2017-11-17","paymentDate":"2017-11-28","value":0.0389,"currency":"USD"},{"executeDate":"2018-01-29","recordDate":"2018-01-30","paymentDate":"2018-02-05","value":0.0269,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IBD\",market:\"US\",delay:false,,,undefined,":{}}}